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Abstract
Background: There is increasing evidence that opioid analgesics may interfere with tumour growth. It is currently thought
that these effects are mediated by transactivation of receptor tyrosine kinase (RTK)-controlled ERK1/2 and Akt signalling.
The growth of many breast cancer cells is dependent on hyperactive ErbB receptor networks and one of the most successful
approaches in antineoplastic therapy during the last decade was the development of ErbB-targeted therapies. However, the
response rates of single therapies are often poor and resistance mechanisms evolve rapidly. To date there is no information
about the ability of opioid analgesics to interfere with the growth of ErbB-driven cancers.
Methods and Principal Findings: Here we demonstrate that ErbB2 overexpressing BT474 human breast cancer cells carry
fully functional endogenous m-opioid receptors. Most interestingly, the acute opioid effects on basal and Heregulin-
stimulated ERK1/2 and Akt phosphorylation changed considerably during chronic Morphine treatment. Investigation of the
underlying mechanism by the use of protein kinase inhibitors and co-immunoprecipitation studies revealed that chronic
Morphine treatment results in rearrangement of the ErbB signalling network leading to dissociation of ERK1/2 from Akt
signalling and a switch from ErbB1/ErbB3 to ErbB1/ErbB2-dependent cell growth. In chronically Morphine-treated cells
Heregulin-stimulated ERK1/2 signalling is redirected via a newly established PI3K- and metalloproteinase-dependent
feedback loop. Together, these alterations result in apoptosis of BT474 cells. A similar switch in Heregulin-stimulated ERK1/2
signalling from an ErbB2-independent to an ErbB2-, PI3K- and metalloproteinase-dependent mechanism was also observed
in k-opioid receptor expressing SKBR3 human mammary adenocarcinoma cells.
Conclusions and Significance: The present data demonstrate that the ErbB receptor network of human breast cancer cells
represents a target for chronic Morphine treatment. Rearrangement of ErbB signalling by chronic Morphine may provide a
promising strategy to enhance the sensitivity of breast cancer cells to ErbB-directed therapies and to prevent the
development of escape mechanisms.
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Introduction
Opioids are potent analgesics and widely used for anaesthetic
pre-medication and management of cancer pain. They mediate
their action via specific binding sites (d, k, m) that belong to the
family of G protein-coupled receptors. Opioid receptors are
predominantly expressed in neuronal tissues and inhibit neuronal
excitability by regulating their ‘‘classical’’ effector systems adenylyl
cyclase, potassium channels and voltage-dependent calcium
currents [1]. Beside this, opioid receptors may also regulate the
activity of a variety of mitogen-activated protein (MAP) kinases,
including Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/
2), c-Jun N-terminal Kinase (JNK), p38, Signal Transducer and
Activator of Transcription 5 (STAT5) and Protein Kinase B
(PKB/Akt) [2,3]. Activation of these ‘‘non classical’’ opioid
effector systems is mediated via transactivation of receptor tyrosine
kinase (RTK)-associated ERK1/2 and Akt signalling pathways
[4,5]. Due to the ability of opioid receptors to regulate the
dominant RTK system in a given cellular context [6], chronic
opioid treatment might provide a means to selectively interfere
with tumour cell growth. Because the opioid effects on tumour cell
proliferation and apoptosis reported so far are rather discrepant
and role of opioid receptors in these studies was not always clear
[7,8], the aim of the present study was to investigate chronic
Morphine regulation of RTK-dependent cell growth in a defined
tumour cell model carrying endogenous m-opioid receptors.
The human Epidermal Growth Factor (EGF) Receptor family
(ErbB, also termed HER) consists of four members (ErbB1-4) and
belongs to subclass I of the superfamily of RTKs. They are
activated by more than 10 different growth factor ligands with
partly overlapping (EGF, HB-EGF, TGF-a, and Betacellulin) or
more discrete (Neuregulins) receptor specificities [9]. ErbB
receptors are transmembrane receptors consisting of an extracel-
lular ligand binding domain, an intracellular kinase domain and
an intracellular C-terminal tail. Ligand binding favours receptor
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dimerization, which in turn leads to activation of the intracellular
kinase domain and autophosphorylation of distinct tyrosine
residues in the C-terminal tail. These provide docking sites for
binding of the Shc/Grb2/SOS complex linking ErbB receptors to
activation of the mitogenic Ras/Raf/ERK1/2 signalling module
[10]. Although structurally highly homologous, individual ErbB
receptors differ with respect to ligand binding and kinase activity.
Most importantly, there is currently no endogenous ligand known
for ErbB2 [11], whereas ErbB3 lacks catalytic tyrosine kinase
activity [12]. Thus, both receptors must undergo heterodimeriza-
tion for signalling. While ErbB2 is considered a signal amplifier,
activated ErbB3 signal through their dimerization partner. In
ErbB1/ErbB3 heterodimers, ligand activation of ErbB3 results in
ErbB1-mediated stimulation of the Ras/Raf/ERK1/2 pathway.
While all ErbB family members are able to cross-regulate the anti-
apoptotic Phosphatidylinositol 3-kinase (PI3K)/Akt pathway in a
Ras-dependent manner, ErbB3 may also directly activate all 3
regulatory subunits of PI3K in the presence of ligand activated
binding partners [13]. Due to the ability of ErbB receptors to form
multiple homo- and heterodimers that considerably differ in their
signalling capacity, alterations in receptor abundance and
dimerization will have dramatic consequences on mitogenic and
anti-apoptotic signalling [9].
Human BT474 breast cancer cells were originally isolated from
a solid, invasive ductal carcinoma of the breast from a 60 years old
woman [14]. These cells are characterized by a dysregulated ErbB
receptor system, because they overexpress the ErbB2 receptor
[11]. ErbB2 is present in about 25–30% of breast cancer patients
[15] and is associated with poor prognosis and high relapse rate
[11]. BT474 cells also carry physiologic levels of ErbB1 and ErbB3
and low levels of ErbB4 [16], providing them a suitable model
system for investigating the impact of ErbB signalling on tumour
cell growth and ErbB2-targeted anti-tumour strategies [17]. In the
present study we demonstrate that BT474 cells carry endogenous
m-opioid receptors and that chronic Morphine treatment attenu-
ates Heregulin-induced cell growth and migration. The underlying
mechanism involves dissociation of Heregulin-induced ERK1/2
and Akt signalling from a common ErbB1/ErbB3 to separate
ErbB1/ErbB2 and ErbB1/ErbB3 mechanisms resulting in PI3K-
dependent cell growth. Similar chronic Morphine effects on ErbB
signalling were also observed in ErbB2 overexpressing SKBR3
human mammary adenocarcinoma cells that carry endogenous k-
opioid receptors. These results demonstrate that chronic Mor-
phine treatment is able to interfere with the growth characteristics
of opioid receptor expressing tumour cells by rearrangement of the
ErbB receptor system. Such a mechanism might provide a
promising strategy to enhance the sensitivity of ErbB-directed
antineoplastic strategies and to prevent escape mechanisms.
Materials and Methods
Materials
Foetal calf serum and cell culture reagents were from Pan
Biotech. Forskolin, human recombinant insulin, 3-isobutyl-1-
methylxanthin (IBMX), (-)-Naloxone-HCl, and all standard
laboratory reagents were from Sigma-Aldrich. (-)-Morphine-HCl
was from Merck, Heregulin (C-terminal fragment of Heregulin b1)
from R&D Systems, recombinant epidermal growth factor (EGF)
from Bachem and [3H]DAMGO (30–60 Ci/mmol) from Perki-
nElmer. Tyrphostin AG1478, AG825, Epigallocatechingallat
(EGCG) and Wortmannin, were from Calbiochem. Protein A-
agarose beads and dithiobis-(succinimidyl propionate) (DSP) were
purchased from Thermo Scientific. Anti-G protein antibodies
have been produced in our laboratory (Gia2, Gia3, Gsa, Gb) or
were obtained from Gramsch Laboratories (Gq/11a, G12a, G13a,
G14a). Primary antibodies recognizing ERK1/2, phospho-ERK1/
2 [Thr202/Tyr204], Akt, phospho-Akt [Ser473], ErbB1, ErbB2,
ErbB3, ErbB4, b-tubulin as well as cleaved PARP [Asp214] were
from Cell Signalling Technology. Secondary horseradish perox-
idase-conjugated anti-mouse and anti-rabbit IgG were from
Promega and Cell Signalling.
Cell Culture, Chronic Opioid Treatment and Membrane
Preparation
BT474 cells were purchased from Cell Lines Service Inc. and
grown in RPMI 1640 medium supplemented with 10% heat-
inactivated foetal calf serum (FCS), 100 IU/ml Penicillin, 0.1 mg/
ml Streptomycin, 0.2% Enrofloxacin and 0.02 mg/ml Insulin at
37uC in a humidified atmosphere of 5% CO2 in air. SKBR3 cells
were obtained from American Type Culture Collection (ATCC)
and grown in McCoy’s 5A modified medium plus supplements as
above. For experimentation, BT474 cells were seeded onto 96-,
24-, 12- and 6 well dishes as indicated at a density of 0.256104–
56105 cells per well, left to adhere overnight and then subjected to
chronic opioid treatment by the addition of Morphine (10 mM) to
the culture medium for 5 d with medium changes and drug
renewal every other day.
For evaluation of membrane proteins (m-opioid and ErbB
receptors, G proteins) and radioligand binding studies, cells were
grown in 75 or 150 cm2 culture flasks and plasma membranes
were prepared as described [18]. In brief, cells were washed 3
times with ice-cold phosphate-buffered saline (PBS; pH7.4),
scraped into 20 ml of TED buffer (5 mM Tris-HCl, 1 mM
EDTA, and 1 mM DTT; pH 7.4) and then homogenized for
10 sec using an Ultra Turrax. After removal of unbroken cells
(3006g; 10 min), membranes were recovered from the superna-
tant fraction by centrifugation for 30 min at 20,0006g. The
membrane pellet was washed once as above, resuspended in TM
buffer (50 mM Tris-HCl, 5 mM MgCl2; pH 7.4) and stored in
aliquots at 280uC until use.
RT-PCR
Total RNA was isolated using TrifastTM reagent (Peqlab) and
transcribed into cDNA using the Fist Strand cDNA Synthesis KitH
(Fermentas) according to manufacturers protocols. Integrity of
cDNA was controlled by determination of GAPDH. Opioid
receptors (OR) and adenylyl cyclase isoforms (AC) were amplified
using specific primer pairs given in Table 1. All PCR reactions
(50 ml) contained 10 pmol of each primer, 10 ng of cDNA,
0.2 mM dNTPs, 1.25 U Pfu DNA polymerase and 20 mM
MgSO4. Amplified fragments (20 ml) were resolved on a 1.5%
agarose gel, stained with ethidium bromide and visualized under
UV light.
Radioligand Binding
Equilibrium binding studies were performed in triplicate
determination for 2 h at RT in a total volume of 0.2 ml using
the high-affinity m-opioid receptor agonist [3H]DAMGO as the
radioligand (2 nM) and 200–300 mg of membrane protein in TM
buffer as described [19]. Non-specific binding was determined in
the presence of 1 mM DAMGO. Reactions were stopped by rapid
filtration over WhatmanH GF/B glass fibre filters and radioactivity
incorporated was determined by liquid scintillation in a Beckman
LS6500 counter (Beckman Coulter). Maximum binding capacity
was calculated according to the method of DeBlasi [20] using a Kd
of 1.4 nM for the human m-opioid receptor [21].
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cAMP Accumulation
Cells grown in 24 well dishes were washed 3 times with DMEM
containing 25 mM HEPES (DMEH) and 0.1 mM IBMX and
then incubated for 30 min at 37uC. Cells were chilled on ice and
media were replaced by DMEH containing the following
stimulators and inhibitors of adenylyl cyclase: Forskolin (1 mM),
Morphine (10 mM) and Naloxone (100 mM). Reactions were
conducted for 15 min at 37uC and stopped by the addition of
0.75 ml 50 mM HCL per well. The amount of cAMP produced
was measured by ELISA after acetylation of the samples.
Cell Growth
Cells were cultured in 24 well plates for 5 (BT474) or 3
(SKBR3) days in insulin-free growth medium in the absence or
presence of Morphine (10 mM), Naloxone (100 mM) and Here-
gulin (40 ng/ml) as described [22]. Cells were then washed twice
with 0.5 ml PBS and fixed for 30 min at RT with 0.25 ml 20%
methanol in PBS containing 0.1% crystal violet. The dye solution
was aspirated, cells were washed extensively with PBS and finally
solubilised for 2 h in 0.25 ml 0.1 M citric acid per well. Colour
intensity was determined after 10 fold dilution at l= 492 nm in a
TecanH Spectra Multiplate Reader. Background staining obtained
from cells on the same plates fixed on day 0 was subtracted.
Scratch Assay
Cell migration was evaluated using the in vitro scratch assay as
described [23]. BT474 cells (46105/well) were seeded onto 6 well
culture dishes containing poly-l-lysine-coated cover slips to yield
90% sub confluent monolayers after 5 d of culture in the absence
(control) or presence of Heregulin (40 ng/ml), Morphine (10 mM)
and Naloxone (100 mM) as indicated. Then, a scratch was made
through the center of the well using a 200 ml pipette tip. Detached
cells were removed and cells were cultured for another 24 h in
complete medium containing the above ligands. Cells were then
washed and fixed with 2% paraformaldehyde, before cell
migration into the open area was assessed using an Olympus
BH2 microscope.
Cell Proliferation
DNA synthesis was determined for 2 h in 96 well plates using
the BrdU Cell Proliferation ELISA (Roche Diagnostics) according
to the manufacturers instruction. Media were removed and cells
were stimulated for 2 h at 37uC with Heregulin b1 (40 ng/ml) and
Morphine (10 mM) dissolved in 0.1 ml of insulin-deficient growth
medium containing 10 mM BrdU. Reactions were stopped; cells
were fixed and incubated with 0.1 ml anti-BrdU antibody coupled
to horseradish peroxidase. After the addition of substrate, colour
reaction was measurement at l= 405 nm. All experiments were
done in triplicate determination.
ERK1/2 and Akt Phosphorylation
Cells grown in 12 well plates were washed and equilibrated for
30 min at 37uC in DMEH containing 0.1% BSA before cells were
stimulated for 5 min with Heregulin-b1 (40 ng/ml), EGF
(100 ng/ml), Morphine (10 mM) and Naloxone (100 mM) as
indicated. Reactions were stopped on ice and cells were solubilized
in 0.5 ml Laemmli sample buffer. In some experiments, the
following protein kinase inhibitors were added during the
equilibration period at the concentrations given: ErbB1 inhibitor
AG1478 (5 mM), ErbB2 inhibitor AG825 (50 mM), PI3K inhibitor
Wortmannin (1 mM) and the matrix metalloproteinase inhibitor
EGCG (10 mM). The activation state of ERK1/2 and Akt was
determined by Western blot using phospho-specific antibodies as
described below.
Apoptosis Assays
Stress-induced apoptosis was evaluated in 12 well dishes by
culturing the cells for 6 h in serum-reduced growth medium (0.5%
FCS) in the absence or presence of Morphine (10 mM), Naloxone
(100 mM) and Heregulin (40 ng/ml). Reactions were stopped by
removal of the medium and solubilisation of the cells in 0.5 ml
Laemmli sample buffer. Apoptosis was determined by Western
blot using an antibody recognizing cleaved PARP.
Western Blot Analysis
Samples were cleared by centrifugation (10,0006g; 5 min) and
proteins were resolved by electrophoresis over 8% (ErbB receptors)
or 10% (Akt, ERK1/2, G proteins, PARP) polyacrylamide gels as
Table 1. Primers and reaction conditions used for amplification of adenylyl cyclases, opioid receptors and GAPDH in human breast
cancer cells.
Target Forward Primer Reverse Primer Temp. Cyc.
AC1 59-CCGAGTTGGCATCAATGTTGGC 59-TCCTCAGTCACCTGGATTCTGC 56uC 35
AC2 59-CAGCATCTCTTCAGACCTCGC 59-CCGGAATGGAGGCAAACATG 57uC 30
AC3 59-GAAGACAAGTCCGAGAGAGAGC 59-TCTTCTACCACCTGAATGTTGC 57uC 30
AC4 59-TCTCTCCAACTTCATCATCC 59-ACACTGATGAGAGGCAGAGACC 56uC 35
AC5 59-ACAGGAGCACAACATCAGCG 59-TGAAGAAGTCTATGGCGTTGGC 58uC 30
AC6 59-TATGACCTACTGCTTGGCGTCC 59-TAGTAGAGTTCATCATTGCGGC 57uC 30
AC7 59-TGGTGCTCTTCAACCTCTCC 59-CTGTCTGGAGAGTGTAAGCAGG 56uC 35
AC8 59-TCGGCTCTGGTCCTCATCAC 59-GTTCTTCAAGGGTATCGACTTG 56uC 35
AC9 59-GAGTTCGCCAAGGAGATGATGC 59-TACAGGTAGGTCTTCATCTGGC 59uC 35
m-OR 59-ATGAAGACTGCCACCAACATCTAC 59-GAAGAGAGGATCCAGTTGCAGAC 60uC 30
d-OR 59-GATGCGCTGGCCACCAGCAC 59-GAACACGCAGATCTTGGTCAC 58uC 30
k-OR 59-ACATTGCCGTGTGCCACCCC 59-TGCCACCACCACCAGGACCA 60uC 30
GAPDH 59-CAAGGTCATCCATGACAACTTTG 59-GTCCACCACCCTGTTGCTGTAG 58uC 30
doi:10.1371/journal.pone.0053510.t001
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described [6]. Proteins were then blotted onto PVDF-membranes,
blocked and incubated overnight at 4uC with primary antibodies
for phospho-specific ERK1/2 and Akt (1/2,000), ErbB receptors
(1/1,000), PARP (1/1,000), G proteins (1/2,000) and b-tubulin (1/
4,000) diluted in TBS/T/BSA (50 mM Tris-HCL, pH 8.0,
150 mM NaCl, 0.05% Tween 20, 0.1% BSA). Blots were washed,
incubated with secondary peroxidase-conjugated IgG and devel-
oped using enhanced chemiluminescence (ECL). Immunoreactive
bands were quantitated by video densitometry using the Herolab
E.A.S.Y. RH-3 system.
Determination of Protein Abundance and
Immunoprecipitation
The presence of G proteins and ErbB receptors was determined
in membranes using specific antibodies as described [6]. The
formation of distinct ErbB receptor dimers was examined by
immunoprecipitation experiments according to Garrett et al. [24]
in cells chronically treated with Morphine (10 mM; 5 d) or not
(control). Cells of a 75 cm2 flask were washed 3 times in PBS and
stimulated for 10 min at 37uC with Morphine (10 mM) and
Heregulin (40 ng/ml) in serum-free RPMI 1640 medium
containing 0.1% BSA. Cells were then placed on ice, washed 3
times with PBS and cross-linked for 2 h with 5 mM DSP in PBS.
Reactions were quenched with 10 mM Tris-HCl and membranes
were prepared. Protein complexes were solubilized for 1 h at 4uC
in TN buffer (10 mM Tris-HCl, 100 mM NaCl; pH 7.4)
containing 1% Triton X 100, 1 mM phenylmethylsulfonyl fluoride
and 4% Complete protease inhibitor cocktail (Roche Diagnostics).
Samples were diluted 1/10 in TN buffer, cleared by centrifugation
(10,0006g; 5 min) and equal amounts of solubilisates were
subjected to immunoprecipitation overnight with anti-ErbB1
antibody (dilution 1/500) and 40 ml of Protein A-agarose beads.
Immuncomplexes were washed 5 times with TN buffer containing
0.1% Triton X 100, cleaved by incubation for 5 min at 95uC in
0.1 ml of Laemmli sample buffer and subjected to gel electropho-
resis.
Cytochemistry
Induction of apoptosis was determined by Annexin V-FITC/
propidium iodide staining of cells grown on poly-l-lysine-coated
cover slips using the Annexin V-FITC Apoptosis Detection Kit
(Bender MedSystems) as described [5]. Cells were then fixed for
30 min at RT with 2% paraformaldehyde in PBS before
specimens were mounted using VectaMount TM AQ Aqueous
Mounting Medium (Vector Laboratories) and cells were examined
by confocal microscopy (Carl Zeiss) using an 636/1.4 oil
immersion objective.
Statistics
All data are expressed as the mean 6 S.E. of the number or
experiments given in the text. Statistical differences between two
groups were analyzed by Student`s t test for unpaired data.
Multiple comparisons were done by ANOVA followed by the
Tukey post-hoc test.
Results
Characterization of Opioid Receptors in BT474 Cells
To evaluate the specificity of acute and chronic opioid effects on
human BT474 breast cancer cells, the presence of opioid receptors
was determined first. RT-PCR experiments revealed the exclusive
expression of m-opioid receptors in this cell line (Fig. 1a). Receptor
density was determined by equilibrium binding studies using the m-
opioid receptor selective peptide agonist [3H]DAMGO as the
radioligand. The results show that BT474 cells contain about
7.362 fmol of m-opioid receptors per mg of membrane protein
(n = 5) and that chronic Morphine treatment does not affect
receptor abundance (7.462 fmol per mg of membrane protein;
n = 3). The ability of m-opioid receptors to mediate cellular effects
depends on the presence of adequate G proteins and effector
systems. As shown in Fig. 1b, BT474 cell membranes carry diverse
members of the family of inhibitory (Gia2, Gia3), stimulatory
(Gsa), Gq (Gq/11a) and G12 (G12a, G13a, G14a) G proteins,
allowing m-opioid receptors to regulate multiple intracellular
signalling pathways. Because they also express several adenylyl
cyclase isoforms (AC 1–5, 9; Fig. 1c), the functional activity of m-
opioid receptors was assessed by their ability to regulate
intracellular cAMP production. Indeed, acute m-opioid receptor
activation by Morphine (10 mM) significantly inhibits intracellular
cAMP generation by about 53%, an effect almost completely
blocked by Naloxone (100 mM). In chronically Morphine (10 mM,
5d)-treated cells an acute Morphine challenge is still able to inhibit
cAMP production by about 48% (Fig. 1d). These results
demonstrate that BT474 cells carry fully functional endogenous
m-opioid receptors and that chronic Morphine treatment does not
desensitize m-opioid receptor function providing an essential
prerequisite to induce regulatory changes on post-receptor levels.
Inhibition of Cell Growth and Migration by Morphine
The growth of human BT474 breast cancer cells is driven by
overexpressed ErbB2 receptor [11]. Due to the potential capacity
of m-opioid receptors to cross-regulate RTK signalling pathways
[25], the ability of Morphine to interfere with BT474 cell growth
was determined. Chronic exposure of the cells to Morphine
slightly attenuates basal cell growth by about 11% as determined
by crystal violet staining. However, the inhibitory opioid effect is
much more pronounced when cells were cultured in the presence
of the ErbB3 receptor agonist Heregulin. Chronic Heregulin
treatment produces mitogenic effects and increases cell number by
about 47%. Co-incubation of the cells with Morphine now
significantly attenuates ErbB3-driven cell growth by about 49%.
Inhibition of both basal and Heregulin-stimulated cell growth by
Morphine is completely blocked by the opioid receptor antagonist
Naloxone (Fig. 2a). In addition, treatment of BT474 cells with the
inactive stereoselective enantiomer (+)-Morphine failed to affect
cell growth (not shown), excluding a receptor-independent effect
on mitochondrial pH due to the alkaloid structure of Morphine.
Opioids have been shown to regulate a number of different
aspects of cell growth in tumour cell lines [26]. To gain a first
indication as to whether Morphine might also interfere with
Heregulin-stimulated BT474 cell migration, cell scratch assays
were performed on cells growing on poly-l-lysine coated cover
slips. As shown in Fig. 2b, Heregulin (40 ng/ml) treatment for 5 d
produces morphological changes and induces cell migration into
the gap 24 h after scratching. Co-incubation of the cells with
Morphine (10 mM, 5d) prevents cell differentiation and migration
into the open field, an effect that was partially blocked in the
presence of Naloxone (100 mM). These results indicate that
chronic Morphine treatment interferes with cell migration by
preventing cell-matrix or cell-cell interactions.
Regulation of Cell Proliferation by Morphine
Inhibition of BT474 cell growth by chronic Morphine treatment
may be due to attenuation of cell proliferation and/or inhibition of
cell survival. To discriminate between these two possibilities, the
effect of acute and chronic Morphine treatment on ERK1/2
stimulation was determined. Most interestingly, acute m-opioid
receptor activation produces discrepant effects on ERK1/2
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phosphorylation, depending on whether basal or Heregulin-
stimulated activities were measured in control or chronically
Morphine exposed cells. In control cells, acute m-opioid receptor
activation using a maximum effective concentration of Morphine
(10 mM; determined in preliminary experiments) results in
elevation of basal ERK1/2 phosphorylation, but significantly
attenuates Heregulin (ErbB3)-induced ERK1/2 activation by
about 17%. Chronic Morphine treatment (10 mM, 5d) results in
elevation of basal and Heregulin-stimulated ERK1/2 phosphor-
ylation. Under these conditions, acute m-opioid receptor activation
now significantly enhances ErbB3-stimulated ERK1/2 activity by
about 14% (Fig. 3a). The increase in basal and Heregulin-
stimulated ERK1/2 activity by chronic Morphine treatment is
also given in Fig. 3b.
Similar results were observed when cell proliferation was
examined by determination of DNA synthesis for 2 h using the
BrdU assay. Again, acute m-opioid receptor activation in control
cells significantly stimulates basal and inhibits Heregulin-stimulat-
ed cell proliferation by about 16% and 10%, respectively. Chronic
Morphine treatment completely abolishes the ability of acute m-
opioid receptor activation to stimulate basal cell proliferation and
attenuates the overall effect of Heregulin by about 16%. In these
cells, acute m-opioid receptor activation now significantly enhances
ErbB3-stimulated cell proliferation by nearly 10% (Fig. 3c). These
results demonstrate that Morphine is able to regulate mitogenic
signalling in human BT474 breast cancer cells and that the kind of
acute m-opioid receptor effect produced largely depends on the
activation state of the cell. In addition, they also indicate that
chronic Morphine treatment alters the ErbB receptor system
controlling the growth of BT474 cells.
Morphine Regulation of Akt Signalling
The finding that chronic Morphine treatment attenuates basal
and Heregulin-stimulated cell growth in the presence of an
enhanced mitogenic m-opioid receptor activity suggests that
additional mechanisms must exist that shortens the lifespan of
the cells. Therefore, we investigated whether chronic Morphine
treatment would possibly attenuate cell survival by inhibition of
Akt phosphorylation. As shown in !Fig. 4a, BT474 cells display
basal levels of Akt phosphorylation, which are stimulated after
activation of ErbB3 receptors by Heregulin. Chronic morphine
treatment results in elevation of both basal and Heregulin-
stimulated Akt activities. Acute m-opioid receptor activation fails to
affect basal and Heregulin-stimulated Akt signalling in both
control and chronically Morphine-treated cells. The increase in
basal and Heregulin-stimulated Akt activity after chronic Mor-
Figure 1. Characterization of m-opioid receptors in BT474 cells. (A) Detection of m-opioid receptors by RT-PCR. Reactions contained 10 ng of
cDNA from BT474 cells or from the corresponding cloned receptors (Cn). Only a 293 bp fragment of the m-opioid receptor is present (arrow). Control
PCRs with primers for GAPDH or water instead of cDNA demonstrated the integrity of cDNA and the specificity of the RT-PCR reaction. Ladder:
100 bp. (B) Determination of G proteins in membranes from BT474 cells by Western blot using subtype-specific antibodies. BT474 cells contain
inhibitory Gia2 and Gia3 as well as stimulatory Gsa subunits. They also contain Gq/11a, G12a, G13a, G14a and Gb subunits. Membranes of MCF-7 cells
served as control. (C) Identification of adenylyl cyclase (AC) isoforms in BT474 cells by RT-PCR. Reactions contained 10 ng of cDNA and primer pairs
for all mammalian AC types. The following fragments were amplified (arrows): AC type 1 (143 bp), 2 (323 bp), 3 (259 bp), 4 (368 bp), 5 (312 bp), and 9
(325 bp). The quality of cDNA was verified by amplification of GAPDH, the specificity by using water instead of cDNA. Ladder: 100 bp. (D) Regulation
of intracellular cAMP production by opioids. Control and chronically Morphine treated BT474 cells were stimulated for 15 min with Forskolin (10 mM).
m-Opioid receptor-mediated inhibition of cAMP production was assessed in the presence of Morphine (10 mM). Receptor specificity was determined
by co-incubation with Naloxone (100 mM). The data shown are from 3 experiments. ***; significantly different at p,.001. n.s.; not quite significant.
doi:10.1371/journal.pone.0053510.g001
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phine treatment is demonstrated separately in Fig. 4b. These
results demonstrate that chronic Morphine treatment increases
basal and Heregulin-stimulated cell survival despite the overall
attenuation of cell growth.
Induction of Apoptosis by Chronic Morphine
To explain this apparent discrepancy, we examined the
induction of apoptosis by chronic Morphine treatment by two
different experimental approaches. We first compared the effect of
Morphine on stress-induced apoptosis in control and chronically
morphine treated BT474 cells by means of PARP cleavage. In
control cells, serum starvation for 6 h failed to induce PARP
cleavage. Apoptosis was induced only in the presence of Heregulin
during the starvation period. Co-incubation of the cells together
with Morphine had no further effect on PARP cleavage.
Completely different results were obtained in chronically Mor-
phine-treated cells. Here, serum starvation alone was already
sufficient to induce PARP cleavage. The induction of apoptosis
was further enhanced by the addition of Heregulin and Morphine,
with their individual effects being additive (Fig. 4c). Similar results
were obtained when apoptosis was determined by Annexin V/
propidium iodide staining of the cells. Cultivation of BT474 cells
on cover slips for 5 d in complete growth medium resulted in
adherent patches that are negative for Annexin V-FITC staining.
Addition of Morphine (10 mM) during the incubation period
resulted in cell rounding, strong Annexin V binding and nuclear
propidium iodide incorporation, which is indicative for the
induction of apoptosis. As observed in the cell migration assay,
chronic Heregulin treatment (40 ng/ml) produced morphological
changes towards a more differentiated cell shape and induced of
early steps of apoptosis as demonstrated by acquiring a polygonal
cell shape and bright Annexin V-FITC staining. Concomitant
treatment with Morphine prevented cell differentiation and
induced apoptosis as indicated by cell rounding and nuclear
propidium iodide incorporation. This chronic Morphine effect
again is completely blocked by Naloxone (Fig. 4d). Together, these
results demonstrate that chronic Morphine treatment of BT474
cells induces apoptosis and enhances Heregulin-stimulated cell
fate.
Figure 2. Regulation of BT474 cell growth and migration by Morphine. (A) BT474 cells were cultured for 5 d in the presence or absence of
Morphine (10 mM), Naloxone (100 mM), and Heregulin (40 ng/ml), before cell growth was determined by crystal violet staining. Top: Photograph of
tissue culture wells from a representative experiment before solubilisation of the dye. Bottom: Data of n= 6 independent experiments normalized to
controls. Note that co-incubation of the cells with Morphine significantly attenuates Heregulin-stimulated cell growth (**, p,.005). (B) BT474 cell
migration was assessed by the scratch assay done in cells grown for 5 d in the absence (control) or presence of Heregulin (40 ng/ml), Morphine
(10 mM) and Naloxone (100 mM) as indicated. After scratching, cells were kept for another 24 h in the presence of the above ligands, before images
were acquired using an Olympus BH-2 microscope (406magnification). The figures shown are representative for 3 independent experiments yielding
qualitatively similar results.
doi:10.1371/journal.pone.0053510.g002
Morphine Regulation of ErbB Signalling
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e53510
Chronic Morphine Treatment Alters ErbB Receptor
Signalling
The growth characteristics of cancer cells are determined by the
signalling strength and duration of individual ErbB receptor
homo- and heterodimers [9]. To obtain a first indication for
whether changes in the ErbB receptor network would account for
the differences observed in mitogenic m-opioid receptor signalling
after chronic Morphine treatment, several components of receptor
tyrosine kinase-stimulated ERK1/2 and Akt signalling pathways
were analysed by the use of established protein kinase inhibitors.
ErbB2-overexpressing BT474 cells contain physiologic levels of
ErbB3 receptors that are essential for ErbB2-driven cell growth
[27]. To our surprise, inhibition of catalytic ErbB1 function by the
tyrphostin analogue AG 1478 completely blocked all aspects of
basal, Morphine- and Heregulin-stimulated ERK1/2 and Akt
phosphorylation in both control and chronically morphine treated
cells, indicating that ErbB1 must represent the obligatory binding
partner in all ErbB receptor dimers. In control cells, blockade of
Figure 3. Regulation of BT474 cell proliferation by Morphine. (A) Determination of ERK1/2 activation in control and chronically Morphine
(10 mM; 5d)-treated cells. Reactions were for 5 min at 37uC in the presence or absence of Morphine (10 mM), Naloxone (100 mM) and Heregulin
(40 ng/ml), before ERK1/2 phosphorylation was determined by Western blot using a phospho-specific antibody. Samples from control and chronically
Morphine-treated cells were run on the same gel. Immunoreactivity was quantified by video densitometry and normalized to Heregulin-stimulated
values in control cells, which were set to 100%. Overall ERK1/2 abundance (42 and 44 kDa forms) was determined on the same samples using a pan
reactive ERK1/2 antibody. Equal protein loading was verifies by staining with a b-tubulin antibody. Insets show representative Western blots. *;
significantly different at p,.05 of n = 8 (control) and 6 (chronic Morphine) independent experiments. (B) Direct comparison of basal and Heregulin
(40 ng/ml)-stimulated ERK1/2 activities in control and Morphine (10 mM; 5d)-treated cells. The same blot was stained for phospho-ERK1/2, pan-ERK1/2
and b-tubulin. Note that chronic morphine treatment elevates both basal and Heregulin (40 ng/ml)-stimulated ERK1/2 phosphorylation leaving
overall ERK1/2 abundance unaffected. (C) Evaluation of cell proliferation by BrdU incorporation. Control and chronically Morphine (10 mM; 5 d)-
treated cells were cultured for 2 h in the presence of 10 mM BrdU, before the amount incorporated was determined by ELISA. Data are from two
independent experiments done in triplicate and normalized to controls, which were set 100%. *; statistically different at p,.05, ***; statistically
different at p,.001.
doi:10.1371/journal.pone.0053510.g003
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Figure 4. Regulation of cell survival and apoptosis by Morphine. (A) Determination of Akt activation in control and chronically Morphine
(10 mM; 5d)-treated cells. Cells were incubated for 5 min at 37uC in the presence or absence of Morphine (10 mM), Naloxone (100 mM) and Heregulin
(40 ng/ml), before Akt phosphorylation was determined by Western blot using a phosphor-specific antibody. The overall amount of Akt was
determined by a phosphorylation-insensitive antibody. Insets show representative Western blots of the corresponding proteins (60 kDa) and b-
tubulin (loading control). Immunoreactive bands were quantified and normalized to Heregulin-stimulated values in control cells, which was set to
100%. The data shown are from n=4 independent experiments. (B) Comparison of basal and Heregulin (40 ng/ml)-stimulated Akt activation in
control and Morphine (10 mM; 5d)-treated cells. Samples were run on the same gel and stained for phospho-Akt, total Akt and b-tubulin as loading
control. Note that chronic morphine treatment increases basal and Heregulin (40 ng/ml)-stimulated levels of Akt phosphorylation. (C) Determination
of PARP cleavage in BT474 cells. Cells were cultured in the absence (control) or presence of Morphine (10 mM; 5 d), before cells were washed and
grown for an additional 6 h in serum-free Medium either in the absence or presence of Heregulin (40 ng/ml) Morphine (10 mM) and Naloxone
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ErbB2 receptor function by AG825 had no effect on basal and
Heregulin-stimulated ERK1/2 and Akt signalling. In contrast,
AG825 exclusively attenuated Heregulin-stimulated ERK1/2
activation in chronically Morphine-treated cells. Because AG825
also fails to affect Heregulin-stimulated Akt signalling, the ErbB1/
ErbB2 heterodimer appears to mediate ErbB3-stimulated ERK1/
2 signalling in Morphine-treated cells. Pre-incubation of the cells
with the PI3K inhibitor Wortmannin completely blocks Akt
phosphorylation under all conditions. In control cells, Wortman-
nin has no effect on basal and Heregulin-stimulated ERK1/2
phosphorylation. However, it largely attenuates ErbB3-stimulated
ERK1/2 activation in chronic Morphine-treated cells. This result
implies that chronic Morphine treatment of BT474 cells switches
Heregulin-stimulated ERK1/2 signalling from a PI3K-indepen-
dent to a PI3K-dependent mechanism. The contribution of
metalloproteinases on chronic Morphine-induced mitogenic sig-
nalling was finally evaluated by pre-incubation of the cells with
EGCG. To our surprise, blockade of ectodomain shedding by
EGCG selectively attenuates basal and Heregulin-induced ERK1/
2 phosphorylation in chronically Morphine-treated, but not in
control cells. In addition, overall levels of Akt phosphorylation
appear to be reduced as compared to controls. This finding
indicates that activation of ErbB1/ErbB2 heterodimers in
chronically Morphine-treated cells appears to require the release
of an autocrine factor (Fig. 5a). Further studies revealed that the
IGF-1 receptor fails to contribute to chronic Morphine-induced
changes in ERK1/2 and Akt signalling (not shown).
To verify whether ErbB1/ErbB2 heterodimers contribute to
mitogenic signalling in chronically Morphine-treated BT474 cells,
these were pre-treated with AG825 and subsequently stimulated
with EGF. In both control and chronically Morphine-treated cells,
activation of ErbB1 by EGF leads to stimulation of ERK1/2 and
Akt activities, as previously observed for Heregulin. Again,
functional inactivation of ErbB2 by AG825 selectively attenuates
EGF-stimulated ERK1/2 phosphorylation in Morphine-treated
cells (Fig. 5b). Thus, EGF appears to induce the formation of
ErbB1/ErbB2 heterodimers only after chronic Morphine treat-
ment of the cells.
One major mechanism by which the formation of ErbB
receptor dimers may be modulated is by regulation of receptor
quantity. As shown in Fig. 5c, chronic Morphine treatment
differentially regulates the relative abundance of ErbB receptor
types present. By means of Western blot analysis of BT474 plasma
membranes, strong immunoreactive bands were obtained for
ErbB1, ErbB2 and ErbB3 receptors. The ErbB4 receptor signal
was only barely detectable. Chronic Morphine treatment produces
complex changes in ErbB receptor levels. It increases the relative
abundance of ErbB1 and ErbB3 and strongly down-regulates the
amount of ErbB2. The levels of ErbB4 remained unchanged.
Concomitant treatment of the cells with Naloxone at least partly
prevented these changes. These results suggest that chronic
Morphine treatment could possibly alter the formation of
individual ErbB homo- and heterodimers by regulating ErbB
receptor abundance.
To test whether chronic Morphine indeed leads to the
rearrangement of ErbB receptor dimers, co-precipitation studies
using an anti-ErbB1 antibody were performed. In membranes
from control cells, ErbB1 appears to exclusively form heterodimers
with ErbB3. Short-term stimulation of the cells with Heregulin
does not affect ErbB1/ErbB3 heterodimers, but leads to co-
precipitation of traces of ErbB2. Besides ErbB1/ErbB3 heterodi-
mers, chronic Morphine treatment also results in the formation of
ErbB1/ErbB2 heterodimers. Again, short-term stimulation of the
cells with Heregulin did not affect dimer formation (Fig. 5d).
Together, these results demonstrate that chronic Morphine
treatment alters ERK1/2 and Akt signalling in BT474 cells by
the establishment of newly formed ErbB1/ErbB2 heterodimers.
To investigate whether similar alterations are also induced in
other ErbB-driven breast tumour cells, the effect on chronic
Morphine treatment on mitogenic signalling was examined in
SKBR3 human mammary carcinoma cells. These cells carry high
levels of ErbB2 and physiologic levels of ErbB1 and ErbB3 [16].
RT-PCR experiments verified the expression of k-type opioid
receptors in this cells system (Fig. 6a), providing the basis for the
development of chronic Morphine-induced adaptations at the
level of the ErbB network. Although chronic Morphine (10 mM,
3d) treatment produced a subtle increase in the abundance of
ErbB1 in plasma membranes (Fig. 6b), no major effect on cell
growth was found as assessed by crystal violet staining (100 vs.
103.866%, mean 6 SE, n = 5). Nonetheless, the use of protein
kinase inhibitors revealed the induction of profound alterations in
ErbB3-stimulated ERK1/2 signalling by chronic Morphine
treatment. As shown in Fig. 6c, EGF (100 ng/ml) and Heregulin
(40 ng/ml) both stimulate ERK1/2 phosphorylation to about the
same extent in control and chronically Morphine (10 mM, 3d)-
treated cells. In both cells, pre-treatment with the ErbB1 inhibitor
AG1478 not only attenuates ErbB1-, but also ErbB3-stimulated
ERK1/2 activation. This indicates that Heregulin-stimulated
ERK1/2 signalling requires ErbB1 in both control and chronically
Morphine-treated SKBR3 cells. In contrast, pre-incubation of the
cells with AG825, Wortmannin and EGCG specifically attenuated
ErbB3-stimulated ERK1/2 activation in chronically Morphine-
treated, but not in control cells. Thus, chronic Morphine
treatment of SKBR3 cells switches Heregulin-mediated ERK1/2
signalling to a PI3K-, matrix metalloproteinase- and ErbB2-
dependent mechanism comparable to that observed in BT474
cells. These results demonstrate that in tumour cells the
dysregulated ErbB receptor system represents a target for chronic
opioid treatment.
Discussion
There is increasing evidence that opioid analgesics interfere
with several aspects of tumour growth [3]. Here we describe that
human BT474 breast cancer cells endogenously express function-
ally active m-opioid receptors and that chronic Morphine
treatment produces fundamental changes in the ErbB receptor
network resulting in attenuation of Heregulin-stimulated cell
growth. These data add a new dimension on the mechanism of
opioid-stimulated mitogenic signalling, as they demonstrate that
opioid receptors not only transactivate RTK-associated signalling
pathways but also may alter the growth characteristics of tumour
cells by rearrangement of the ErbB receptor system.
The ErbB receptor family integrates a number of auto- and
paracrine signals to regulate normal cell growth, differentiation
(100 mM) as indicated. Samples were analysed by Western blot using an antibody recognizing full length (116 kDa) and cleaved (89 kDa) PARP. The
same samples were blotted for b-tubulin (loading control). (D) Determination of apoptosis by Annexin V/propidium iodide staining. BT474 cells were
cultured on coverslips for 5 d in the presence or absence of Morphine (10 mM), Naloxone (100 mM) and Heregulin (40 ng/ml) alone or in combination
as indicated. Cells were sequentially stained with Annexin-FITC (green), propidium iodide (red), fixed and analysed by confocal microscopy. Bar:
20 mm.
doi:10.1371/journal.pone.0053510.g004
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Figure 5. Analysis of chronic Morphine-induced changes in ErbB signalling pathways. (A) Effect of protein kinase blockers on basal and
Heregulin-stimulated ERK1/2 and Akt phosphorylation. BT474 cells were cultured for 5 d in the absence (control) or presence of Morphine (10 mM),
before the impact of ErbB1 (AG1478), ErbB2 (AG825), PI3K (Wortmannin; Wort.) and metalloproteinases (EGCG) on basal and Heregulin (40 ng/ml)-
stimulated ERK1/2 and Akt signalling was determined by Western blot using phospho-specific antibodies. Controls were kept in the absence of
protein inhibitors. To verify equal protein loading, controls were also stained with overall reactive anti-ERK1/2 and anti-Akt antibodies. (B)
Involvement of ErbB2 on basal and EGF-stimulated ERK1/2 and Akt signalling. Controls and cells chronically exposed to Morphine (10 mM; 5d) were
incubated with or without AG825 (50 mM; 30 min), before ERK1/2 and Akt phosphorylation was determined for 5 min in the absence or presence of
EGF (100 ng/ml). Equal protein loading was verified by staining controls with overall reactive anti-ERK1/2 and anti-Akt antibodies. (C) Regulation of
ErbB receptor abundance by chronic Morphine treatment in BT474 cells. Cells were cultured for 5 d in the presence or absence of Morphine (10 mM)
and Naloxone (100 mM) as indicated and overall ErbB receptor levels were analysed by Western blot using specific antibodies for ErbB1 (175 kDa),
ErbB2 (185 kDa), ErbB3 (185 kDa) and ErbB4 (170 kDa). Equal protein loading was verified by incubation of the blots with an antibody against b-
tubulin. (D) Alteration of ErbB1 containing receptor dimers by chronic Morphine. Controls and chronically Morphine (10 mM; 5 d)-treated BT474 cells
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and development [28]. In many cancers, the ErbB receptor
network is hyperactive and leads to clonal expansion of tumour
cells [29]. Among the best studied examples are human breast
cancers that overexpress the ErbB2 receptor. Because the level of
ErbB2 gene amplification in ErbB2 positive cancers is much
higher than in normal tissue, targeted inactivation of the ErbB2
protein evolved as one to the most promising and successful
antineoplastic strategies in these cancers. The outcome of anti-
ErbB2 treatments, however, is often limited by the induction of
compensatory resistance mechanisms due to the high plasticity of
the ErbB network [17]. In this context, the present study
performed on human BT474 and SKBR3 breast cancer cells
opens a new perspective in order to enhance the sensitivity of
ErbB2-directed treatments and to avoid escape mechanisms. This
idea bases on the finding that chronic Morphine treatment induces
apoptosis in BT474 cells by affecting the specificity of Heregulin-
stimulated ErbB signalling. These effects are mediated by the
formation of ErbB1/ErbB2 heterodimers in chronically Morphine
treated cells that switch tumour cell growth from an ErbB3- to and
ErbB2-dependent mechanism. Opposite changes in ErbB receptor
plasticity have been previously reported for BT474 and SKBR3
mamma carcinoma cells chronically treated with specific anti-
ErbB1 and ErbB2 inhibitors. In these studies, inactivation ErbB1
and ErbB2 receptors restored cell growth by reactivation of ErbB3
and ErbB4 receptor signalling [30] and redirected tumour cell
growth from an ERK1/2 to an Akt-dependent mechanism [24].
The changes in ErbB receptor network by chronic Morphine
treatment were detected by the use of protein kinase inhibitors to
block acute m-opioid receptor-stimulated ERK1/2 and Akt
activity. Although the single use of protein kinase inhibitors may
be endowed with several drawbacks, like non-specific effects, it was
not possible to verify the present results by genetic approaches
because siRNA-mediated knock-down or protein overexpression
per se may alter ErbB signalling and mask possible chronic
Morphine effects. Nevertheless, the use of validated and generally
accepted protein kinase inhibitors in this study provided novel
insight into the composition of ErbB receptor dimers in BT474
and SKBR3 cells. Our experiments suggest that ErbB1 appears to
represent the obligatory binding partner in ErbB receptor dimers,
because pre-treatment of the cells with AG1478 blocked all aspects
of basal and Heregulin-stimulated ERK1/2 and Akt activities. To
our surprise, ERK1/2 signalling was exclusively affected by
AG825 in chronically Morphine treated, but not in control cells.
This suggests that chronic Morphine treatment induces the
formation of ErbB1/ErbB2 heterodimers, which was verified by
our co-immunoprecipitation studies in BT474 cells. Co-immuno-
precipitation also revealed the existence of ErbB1/ErbB3 hetero-
dimers in both naı¨ve and chronically Morphine-treated cells,
substantiating the notion that the growth of BT474 cells is
dependent on ErB3 signalling despite overexpression of ErbB2
[27].
To investigate the role of chronic Morphine treatment on
ErbB3 signalling, Heregulin stimulated ERK1/2 and Akt signal-
ling was investigated in BT474 and SKBR3 cells. In control cells,
Heregulin appears to mediate ERK1/2 and Akt signalling via
activation of single ErbB1/ErbB3 heterodimers. Activation of
ErbB3 in ErbB1/ErbB3 heterodimers has been shown to mediate
signal transduction by transactivation of ErbB1, which in turn
stimulates the Ras/Raf/ERK1/2 cascade by binding the adapter
proteins Shc and Grb2 [31]. Because ErbB3 is deficient of kinase
activity, Heregulin-stimulated Akt signalling must be accomplished
by Grb2/Gab1 mediated cross-regulation of PI3K [32]. After the
introduction of ErbB1/ErbB2 heterodimers, Heregulin-stimulated
ERK1/2, but not Akt signalling became dependent on ErbB2
receptors in BT474 cells. This finding suggests that Akt signalling
is further accomplished by ErbB1/ErbB3 heterodimers, whereas
were stimulated for 5 min with or without Heregulin (40 ng/ml) to form receptor dimers. Proteins were cross-linked and ErbB1 containing dimers
were immunoprecipitated using an anti-ErbB1 antibody. Individual ErbB receptors were determined in whole cell solubilisates (S) and
immunoprecipitates (IP) by Western blot using type-specific antibodies. Equal protein load was verified by determination of IgG heavy chains (Fc).
doi:10.1371/journal.pone.0053510.g005
Figure 6. Regulation of ErbB signalling by chronic Morphine in
SKBR3 cells. (A) Identification of k-opioid receptors in SKBR3 human
mammary adenocarcinoma cells by RT-PCR. Reactions contained 10 ng
of cDNA from SKBR3 cells or plasmid pcDNA3.1 containing the cloned
receptor. A 322 bp fragment of the k-opioid receptor is present in the
cells (arrow). Ladder: 100 bp. (B) Regulation of ErbB receptor
abundance by chronic Morphine treatment. Cells were cultured for 3
d in the presence or absence of Morphine (10 mM) and Naloxone
(100 mM), before membranes were prepared and ErbB receptors were
determined by Western blot using antibodies specific for ErbB1
(175 kDa), ErbB2 (185 kDa) and ErbB3 (185 kDa). Equal protein loading
was determined using an antibody against b-tubulin. (C) Effect of
chronic Morphine treatment on ErbB1- and ErbB3-stimulated ERK1/2
signalling. SKBR3 cells were cultured for 3 d in the absence (control) or
presence of Morphine (10 mM), before the impact of protein inhibitors
AG1478 (ErbB1), AG825 (ErbB2), Wortmannin (Wort; PI3K) and EGCG
(metalloproteinases) on basal, EGF (100 ng/ml)- and Heregulin (40 ng/
ml)-stimulated ERK1/2 phosphorylation was determined by Western
blot. Controls were kept in the absence of protein inhibitors (none).
Total ERK1/2 was determined using an overall reactive antibody.
doi:10.1371/journal.pone.0053510.g006
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ERK1/2 signalling is redirected to ErbB1/ErbB2 heterodimers.
Such a mechanism would require the autocrine release of an EGF-
like ligand by Heregulin, which then transactivates the ErbB1/
ErbB2 heterodimer. In our experiments, blockade of metallopro-
teinase activity by EGCG largely attenuated Heregulin- and EGF-
stimulated ERK1/2 activation, indicating that Heregulin indeed
induces the release of an EGF-like ligand. Reactivation of a
comparable autocrine loop maintaining ErbB2 activity has been
previously described for breast cancer cells chronically treated with
an anti-ErbB2 directed antibody [!33]. In chronically Morphine
treated cells, Heregulin-stimulated ERK1/2 signalling also
became dependent on PI3K, whereas pre-treatment with
Wortmannin is ineffective in control cells. To date, cross-activation
of ERK1/2 signalling by PI3K has been observed only under
distinct conditions, however the underlying cellular mechanism
remain unclear. It has been suggested that PI3K-dependent Ras/
Raf/ERK1/2 signalling is that ErbB1 recruits GAP/SH2
complexes to cell membranes by PIP3 in the presence of low
doses of EGF-like ligands [34]. Although we cannot exclude such a
mechanism, our results suggest that PI3K contributes to the
Heregulin-induced cleavage of EGF-like ligands by metalloprotei-
nase. This would be in line with the finding that PI3K is able to
block a negative feedback loop in ErbB3-driven tumour cells,
resulting in a compensatory activation of the ERK signalling
pathway [35]. The question remains how Heregulin brings about
Akt phosphorylation in chronically Morphine treated BT474 cells.
Despite the lack of catalytic activity, ErbB3 is able to directly
activate PI3K by binding all three regulatory subunits through
their SH-domains [13]. However, phosphorylation of the 6
consensus phosphorylation sites in the C-terminus of ErbB3 is
only induced after ligand-induced activation of an ErbB binding
partner. In this respect, an EGF-like ligand released by Heregulin
might activate accomplish direct Akt signalling via ErbB1/ErbB3
heterodimers in chronically Morphine-treated BT474 cells. Such a
mechanism appears plausible because blockade of metalloprotei-
nase activity in chronically Morphine-treated cells substantially
attenuates the levels of Akt phosphorylation. A model of chronic
Morphine-induced changes in Heregulin-stimulated ERK1/2 and
Akt signalling is shown in !Fig. 7.
In BT474 cells, the functional consequence of the chronic
Morphine-induced alterations in ErbB signalling is the enhance-
ment of Heregulin-induced apoptosis. Morphine is known to
possess pro-apoptotic effects in a number or cell models. Pathways
proposed to be involved in Morphine-induced apoptosis include
an increased expression of pro-apoptotic Bim, decreased expres-
sion of anti-apoptotic Bcl-2 [36] and stabilization of p53 [37]. On
the other hand opioids have also been shown to display strong
anti-apoptotic properties in a number of cell models, which are
mediated by activation of the Akt pathway [5]. On the first view,
the induction of apoptosis in BT474 cells is somewhat surprising,
since chronic Morphine treatment consistently increased basal
levels of Akt phosphorylation. One possible explanation for this
apparent discrepancy is that the switch from an ErbB3- to an
ErbB2-dependent signalling attenuates cell survival by masking
ErbB3 driven Akt signalling. An opposite mechanism has been
described in cancer cells with dominant PI3K signalling in which a
negative feedback loop dampens compensatory Ras/Raf/ERK1/
2 activity, maintaining anti-apoptotic signalling [35]. In this
respect, chronic Morphine-induced ErbB2 signalling may be
viewed as an escape mechanism that blocks Akt signalling.
The mechanism by which chronic Morphine regulates the
rearrangement of ErbB receptor dimers remains to be determined.
One possible explanation would be that Morphine, which acts as a
partial agonist at the m-opioid receptor, produces persistent
inhibitory opioid signalling due to its failure to desensitize the
receptor [38]. Indeed, although present at relatively low levels in
BT474, chronic Morphine treatment had no effect on m-opioid
receptor abundance and signalling, providing an absolute
requirement for the induction of adaptational changes on post-
receptor level. In neuronal cells, such changes are proposed to
contribute to the development of opioid tolerance and dependence
[1]. In non-neuronal cells, chronic Morphine treatment has been
shown to facilitate persistent ERK1/2 signalling by down-
regulation of c-Cbl and blockade of ErbB1 receptor degradation
[18]. Inhibition of protein degradation could explain our finding
that chronic Morphine treatment elevates the abundance of ErbB1
and ErbB3 in BT474 cells. An opposite down-regulation of ErbB2
after chronic Morphine treatment might be the result of
activation-induced cleavage of the receptor, which is typical for
ErbB2-overexpressing cells [39]. Because regulation of ErbB
abundance is a critical determinant for the signalling activity in a
Figure 7. Model of chronic Morphine-induced changes in ErbB
signalling. The scheme depicts the differences in Heregulin-stimulated
ErbB signalling in control and chronically Morphine-treated BT474 cells.
In control cells, stimulation with Heregulin leads to activation of ERK1/2
and Akt signalling via ErbB1/ErbB3 heterodimers. While AG1478 blocks
both Heregulin-stimulated ERK1/2 and Akt signalling, inhibition of PI3K
by Wortmannin specifically prevents Akt signalling. Because ErbB3
phosphorylation and PI3K activation is dependent on the presence of a
dimerized ErbB member with catalytic activity, these results indicate
that Heregulin-stimulated ERK1/2 signalling is predominantly mediated
through ErbB1. The failure of Wortmannin to affect ERK1/2 activation in
control cells further implicates that Heregulin stimulates Akt signalling
via ErbB3. Chronic Morphine treatment alters mitogenic signalling by
rearrangement of ErbB heterodimers. Whereas Heregulin still stimulates
Akt signalling via ErbB1/ErbB3, ERK1/2 signalling is now accomplished
by ErbB1/2 heterodimers. These are activated indirectly by an EGF-like
ligand liberated from Heregulin in a PI3K (Wortmannin)- and
metalloproteinase (EGCG)-dependent manner.
doi:10.1371/journal.pone.0053510.g007
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given cell system [28], quantitative changes in ErbB receptors
represent a potential mechanism by which chronic Morphine
treatment influences the composition of individual ErbB dimers.
Conclusions
The present study demonstrates that chronic Morphine
treatment produces fundamental changes in the ErbB receptor
network of human breast cancer cells that are characterized by
quantitative alterations in the abundance of individual ErbB
receptors, alterations in ErbB dimer formation and the introduc-
tion of an autocrine loop that redirects Heregulin-stimulated
ERK1/2 activation from ErbB1/ErbB3 to ErbB1/2-heterodi-
mers. Although these changes produce no major effect on
Morphine stimulated cell growth and mitogenic signalling, they
become evident when Heregulin-stimulated effects on cell growth
were examined. Direct modulation of ErbB signalling mechanisms
could explain the many discrepant opioid effects on cell growth
and apoptosis observed so far in individual cell systems and may
provide a novel strategy to stabilize certain ErbB dimers in order
to enhance the sensitivity of ErbB-directed anti-tumour therapies
and to avoid the development of drug resistance by preventing
escape mechanisms.
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